J&J’s Bull Case Narrows as Risks Loom Over Growth

Forward-Looking Analysis

Analysts project Johnson & Johnson to report Q1 2026 revenue of approximately $24.8 billion, reflecting year-over-year growth of around 6.8%, aligning with its full-year revenue guidance of $100.5 billion. Analysts expect adjusted EPS to reach $2.55, up from $2.12 in the prior-year quarter. Key institutions like Morgan Stanley and RBC Capital have raised their price targets to $267 and $255, respectively, while maintaining a positive stance. Barclays and UBS also support the stock with "equal weight" and "buy" ratings. Analyst consensus pegs a 10.58 EPS for the full year. highlighting confidence in earnings resilience despite patent cliffs and litigation pressures.

Historical Performance Review

In 2025Q4, Johnson & Johnson delivered revenue of $24.56 billion, net income of $5.12 billion, and EPS of $2.12. Gross profit stood at $16.60 billion, representing a gross margin of 67.6%. These results underscore the company’s ability to maintain profitability amid ongoing patent and litigation headwinds.

Additional News

Johnson & Johnson recently launched the VARIPULSE Pro pulsed field ablation system in Europe, adding potential device revenue growth. Institutional investors including Robinhood Asset Management and Centennial Wealth Advisory increased holdings in Q4 2025, signaling confidence in long-term stability. Additionally, the company shared new TECNIS PureSee data at ASCRS 2026, which may boost its medtech segment. However, ongoing litigation over talc-based products and biosimilar competition remain notable risks.

Summary & Outlook

Johnson & Johnson demonstrates strong financial health with a AAA credit rating, diversified business segments, and consistent revenue growth. The MedTech and Pharmaceutical segments remain key growth drivers, with recent product launches like the VARIPULSE Pro showing potential. However, patent cliffs, litigation exposure, and pricing pressures present risks. Overall, the company is positioned for moderate revenue and EPS growth, with a bullish stance supported by its resilient business model, strong balance sheet, and long-standing dividend record.